Samsung Biologics Plans KRW 3 Trillion Rights Offering

INCHEON, SOUTH KOREA, Aug 27, 2026

KRW 3 Trillion Offering Supports Expansion

Samsung Biologics plans to issue approximately 2.27 million new common shares at an offering price of KRW 1.322 million per share, representing an approximately 15% discount to the reference price. The company expects the offering to raise approximately KRW 3 trillion, equivalent to around 4.90% of its market capitalization based on the previous trading day’s closing price. Existing shareholders will initially receive the opportunity to subscribe to the new shares on a pro-rata basis, with any unsubscribed shares subsequently offered through a general public subscription. Under South Korea’s Capital Markets Act, 20% of the new shares will be allocated to the employee stock ownership association, with the remaining shares made available proportionally to existing shareholders. Subscription rights certificates will also be tradable for shareholders who choose not to participate in the offering.

PolyPeptide Acquisition Broadens CDMO Portfolio

A significant portion of the capital raise is linked to Samsung Biologics’ planned all-cash acquisition of PolyPeptide Group for CHF 1.46 billion, announced in July. The transaction is expected to expand Samsung Biologics’ contract development and manufacturing organization (CDMO) portfolio beyond its established strengths in antibodies and antibody-drug conjugates (ADCs) into peptide-based therapeutics. The expansion is intended to position the company to address growing demand for different therapeutic modalities and provide customers with broader manufacturing capabilities. By adding peptide manufacturing expertise to its existing biomanufacturing platform, Samsung Biologics expects to strengthen its ability to support pharmaceutical and biotechnology companies developing increasingly diverse pipelines. The planned acquisition therefore represents a major component of the company’s broader strategy to diversify its technology and manufacturing portfolio.

Bio Campus II to Drive Manufacturing Growth

The remaining approximately KRW 290 billion from the rights offering is planned for expansion of Bio Campus II in South Korea. Following completion of Plant 5 in 2025, Samsung Biologics has been evaluating the sequential development of Plants 6 through 8, with the company targeting global manufacturing capacity of approximately 1.385 million liters by 2032. The planned expansion is designed to increase production capacity and provide additional infrastructure to support future demand for biopharmaceutical manufacturing. Samsung Biologics currently operates manufacturing capacity across Bio Campus I and II in Korea, as well as a U.S. manufacturing facility in Rockville, Maryland. The company has also secured land for Bio Campus III, establishing a foundation for additional future capacity. The rights offering is expected to progress according to a defined schedule. Samsung Biologics said its securities registration statement is expected to become effective on September 30, 2026, with the new share allocation scheduled for October 6. Subscription for existing shareholders is planned for November 9–10, followed by a general public offering for unsubscribed shares on November 12–13. The newly issued shares are targeted for listing on November 30, 2026. The capital raise reinforces Samsung Biologics’ position as a major global CDMO while supporting its strategy to expand both manufacturing scale and therapeutic modality capabilities. John Rim, President and CEO of Samsung Biologics, said the financing is intended to support the company’s next stage of growth and strengthen its leadership through the planned PolyPeptide acquisition and Bio Campus II expansion. With investments spanning capacity, portfolio and geographic expansion, Samsung Biologics is positioning its manufacturing network to support emerging therapies and evolving pharmaceutical development requirements.

Source: Samsung Biologics press release